// App-Quantinova.ai

DMT49 : Pregnancy Outcomes Following Exposure to Ofatumumab in Patients with MS: Results from the Prim Study

Researchers

Presenter

  • Riley Bove

Principal Investigators

  • Maria Pia Amato

  • Ruth Dobson

  • Kristen M Krysko

  • Sharon Stoll

  • Sandra Vukusic

  • Bassem Yamout

  • Ronald Zielman

  • Krishna Swetha Gummuluri

  • Valentine Jehl

  • Ulf Schulze Topphoff

  • Roseanne Sullivan

  • Kerstin Hellwig

Medical Centers

  • Neurology, American University of Beirut Medical Center

  • University Claude Bernard Lyon 1, VILLEURBANNE, France

  • Harley Street Medical Center

  • Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques

  • Weill Institute of Neurosciences, University of California, San Francisco

  • Department of Neurology, Yale University

  • Department NEUROFARBA, University of Florence

  • Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London

  • IRCCS, Fondazione Don Carlo Gnocchi

  • Department of Neurology, Royal London Hospital, Barts Health NHS Trust

  • Li Ka Shing Knowledge Institute, St. Michael’s Hospital

  • St. Josef-Hospital/Ruhr-University Bochum

  • Division of Neurology, Department of Medicine, St. Michael’s Hospital, University of Toronto TORONTO ON Canada

  • Novartis Pharma AG

  • 6Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon Lyon France

Locations

  • United States

  • Canada

  • France

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Congenital disorder

Disease

  • Congenital anomalies

Biomarkers

  • N/A

Drug/Treatment

  • ofatumumab Intravenous

Outcome

  • N/A

Study Design

  • Non Interventional

Phase

  • NA

Study Id's

  • NCT05634967

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved